StreetInsider.com News Articles

Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain

Mon, 26 Oct 2026 08:00:00 -0400

Company to Attend BIO-Europe in Cologne, Germany, and Present a Scientific Poster at Drug Discovery Chemistry Europe in Barcelona, Spain

REHOVOT, Israel, Oct. 26, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), pioneering company in computational chemistry specializing in AI-based generative design of small molecules for the pharmaceutical and agricultural industries, today announced its participation in two upcoming industry conferences

Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain

Mon, 26 Oct 2026 08:00:00 -0400

Company to Attend BIO-Europe in Cologne, Germany, and Present a Scientific Poster at Drug Discovery Chemistry Europe in Barcelona, Spain

EverGen Infrastructure Announces Record RNG Production for Q3 2026

Thu, 22 Oct 2026 21:53:00 -0400

VANCOUVER, British Columbia--(BUSINESS WIRE)-- EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN) (OTCQB: EVGIF) is pleased to announce production results for the quarter ending September 30, 2026.

Quarterly RNG Production Update

The Company delivered its highest quarterly Renewable Natural Gas (“RNG”) production in Q3 2026.

Corporate RNG production in Q3 2026: 56,064 GJ
2.5% increase compared with Q2 2026
8.3% increase compared with Q3 2025

“Our strongest quarterly production to date reflects the continued consistency and momentum across our RNG portfolio, with production up 8% year over year,” said Chase Edgelow, CEO of EverGen. “We remain focused on operational excellence at

EverGen Infrastructure Announces Record RNG Production for Q3 2026

Thu, 22 Oct 2026 21:53:00 -0400

Quarterly RNG Production Update

The Company delivered its highest quarterly Renewable Natural Gas (“RNG”) production in Q3 2026.

Corporate RNG production in Q3 2026: 56,064 GJ
2.5% increase compared with Q2 2026
8.3% increase compared with Q3 2025

EverGen Infrastructure Announces Record RNG Production for Q3 2026

Thu, 22 Oct 2026 21:53:00 -0400

Quarterly RNG Production Update

The Company delivered its highest quarterly Renewable Natural Gas (“RNG”) production in Q3 2026.

Corporate RNG production in Q3 2026: 56,064 GJ
2.5% increase compared with Q2 2026
8.3% increase compared with Q3 2025

EverGen Infrastructure Announces Record RNG Production for Q3 2026

Thu, 22 Oct 2026 21:53:00 -0400

Quarterly RNG Production Update

The Company delivered its highest quarterly Renewable Natural Gas (“RNG”) production in Q3 2026.

Corporate RNG production in Q3 2026: 56,064 GJ
2.5% increase compared with Q2 2026
8.3% increase compared with Q3 2025

Form 3 Evogene Ltd. For: Oct 06 Filed by: Adler Oz

Thu, 22 Oct 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20261022/27222443.html

Form 3 Evogene Ltd. For: Oct 06 Filed by: Zuloff-Shani Adi

Thu, 22 Oct 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20261022/27222438.html

Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeIL

Tue, 20 Oct 2026 08:00:00 -0400

The roadshow will connect leading Israeli AI-driven drug discovery and biotechnology companies with U.S. investors, pharmaceutical companies, and potential strategic partners

REHOVOT, Israel, Oct. 20, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in AI-driven generative design of small molecules for pharmaceutical and agricultural applications, today announced its participation in the AI

Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeIL

Tue, 20 Oct 2026 08:00:00 -0400

The roadshow will connect leading Israeli AI-driven drug discovery and biotechnology companies with U.S. investors, pharmaceutical companies, and potential strategic partners

Form SCHEDULE 13D/A Evogene Ltd. Filed by: L.I.A. Pure Capital Ltd

Tue, 06 Oct 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20261006/27155584.html

Evogene reaches deal with Pure Capital Group to reshape its board

Tue, 06 Oct 2026 16:00:20 -0400

Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) announced it has entered into a cooperation agreement with L.I.A. Pure Capital Ltd. and Invest Pro Shukai Hon Ltd., collectively referred to as the Pure Capital Group, to resolve disputes that arose following the company's Annual General Meeting held on Sept. 4, 2026.

The Pure Capital Group had contested the voting results from that meeting and, on Sept. 8, 2026, served notice of its intention to initiate a special tender offer under Section 328 of the Israeli Companies Law. Under the cooperation agreement, the group has agreed to withdraw that notice and enter into a

Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors

Tue, 06 Oct 2026 16:00:00 -0400

REHOVOT, Israel, Oct. 6, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced that it has entered into a comprehensive cooperation agreement (the "Agreement") with L.I.A. Pure Capital Ltd. and Invest Pro Shukai Hon Ltd. (together, the "Pure Capital Group") to resolve all outstanding differences between the parties. The agreement is intended to establish

Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors

Tue, 06 Oct 2026 16:00:00 -0400

Form 6-K Evogene Ltd. For: Oct 06

Tue, 06 Oct 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20261006/27155313.html

Form 4 Evogene Ltd. For: Sep 04 Filed by: RECANATI LEON

Wed, 30 Sep 2026 08:13:00 -0400

si-local-file:///var/storage/secattach/20260930/27125692.html

Form 4 Evogene Ltd. For: Sep 04 Filed by: Nimrodi Nir

Wed, 30 Sep 2026 08:09:00 -0400

si-local-file:///var/storage/secattach/20260930/27125670.html

Form 4 Evogene Ltd. For: Sep 04 Filed by: Percy Adrian John

Wed, 30 Sep 2026 08:07:00 -0400

si-local-file:///var/storage/secattach/20260930/27125663.html

Form 4 Evogene Ltd. For: Sep 04 Filed by: Falk Dan Michael

Wed, 30 Sep 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260930/27125656.html

Nasdaq grants Evogene a second 180-day window to meet $1 bid rule

Wed, 30 Sep 2026 07:16:12 -0400

Evogene Ltd. (NASDAQ: EVGN) has received an additional 180-day period, until March 29, 2027, to regain compliance with Nasdaq's minimum bid price requirement, according to a statement from the company.

Nasdaq notified Evogene on March 30, 2026, that its ordinary shares had traded below $1.00 per share for 30 consecutive business days, placing the company in violation of Nasdaq Rule 5550(a)(2). The company was given an initial 180-day period, expiring September 28, 2026, to resolve the issue but did not regain compliance within that timeframe.

Under the extended period, Evogene will regain compliance if its closing bid price reaches at least $1.00

Form 6-K Evogene Ltd. For: Sep 30

Wed, 30 Sep 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260930/27125193.html

Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance

Wed, 30 Sep 2026 07:15:00 -0400

REHOVOT, Israel, Sept. 30, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) (the "Company", "Evogene"), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today reported that the Company received a letter (the "Letter") from the Nasdaq Stock Market LLC ("Nasdaq"), indicating that on March 30, 2026 the Company was notified, based on the previous 30 consecutive business days, that it

Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance

Wed, 30 Sep 2026 07:15:00 -0400

Form EFFECT Evogene Ltd.

Wed, 30 Sep 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260930/27124718.html

Form 6-K Evogene Ltd. For: Jun 30

Mon, 28 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260928/27114566.html